Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bangkok Dusit Medical Services PCLBKK:BDMS -1.02%90 Return-on-Tangible-Equity is 18.51% as of Mar. 2026, which is 5% below its 10-year median of 19.52. GuruFocus rates BKK:BDMS with a GF Score™ of 90/100 and a GF Value™ of ฿28.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Bangkok Dusit Medical Services PCL ranks better than 65.8% on this metric.
The historical rank and industry rank for Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:BDMS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.85 Med: 19.52 Max: 27.1
Current: 18.44
During the past 13 years, Bangkok Dusit Medical Services PCL's highest Return-on-Tangible-Equity was 27.10%. The lowest was 10.85%. And the median was 19.52%.
BKK:BDMS's Return-on-Tangible-Equity is ranked better than 65.8% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs BKK:BDMS: 18.44
Bangkok Dusit Medical Services PCL (BKK:BDMS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bangkok Dusit Medical Services PCL Return-on-Tangible-Equity Related Terms
Bangkok Dusit Medical Services PCL Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Dusit Medical Services PCL Return-on-Tangible-Equity Chart
BKK:BDMS vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Dusit Medical Services PCL Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.51% mean?
Bangkok Dusit Medical Services PCL (BKK:BDMS) has a Return-on-Tangible-Equity of 18.51% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bangkok Dusit Medical Services PCL and its competitors. This is near median its historical median of 19.52. Over the past decade, Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity has ranged from 10.85 to 27.10. According to the industry distribution chart, Bangkok Dusit Medical Services PCL ranks #198 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 34.2%.
Is Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity too high?
Bangkok Dusit Medical Services PCL's current Return-on-Tangible-Equity of 18.51% is near median its 10-year median of 19.52. Over the past 10 years, this metric has ranged from a low of 10.85 to a high of 27.10. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. Bangkok Dusit Medical Services PCL's value of 18.51% is 81.3% above this industry median. Based on the distribution chart, Bangkok Dusit Medical Services PCL ranks #198 out of 579 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Bangkok Dusit Medical Services PCL has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bangkok Dusit Medical Services PCL's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Bangkok Dusit Medical Services PCL ranks #198 out of 579 companies for Return-on-Tangible-Equity. This puts Bangkok Dusit Medical Services PCL in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.21. Bangkok Dusit Medical Services PCL's value of 18.51% is 81.3% above this benchmark. Historically, Bangkok Dusit Medical Services PCL's own Return-on-Tangible-Equity has ranged from 10.85 to 27.10 over the past decade. While the company's 10-year median is 19.52 vs. the industry median of 10.21, Bangkok Dusit Medical Services PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Dusit Medical Services PCL's current Return-on-Tangible-Equity of 18.51% is 81.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bangkok Dusit Medical Services PCL and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Dusit Medical Services PCL's current Return-on-Tangible-Equity is 18.51%, which is near median its own 10-year median of 19.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Dusit Medical Services PCL stock overvalued right now?
Based on GuruFocus' analysis, Bangkok Dusit Medical Services PCL (BKK:BDMS) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿28.09, compared to a current price of ฿19.40 — trading 30.9% below its estimated fair value. The current Return-on-Tangible-Equity is 18.51%, which is near median its 10-year median of 19.52 and 81.3% above the Healthcare Providers & Services industry median of 10.21. Bangkok Dusit Medical Services PCL's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bangkok Dusit Medical Services PCL (BKK:BDMS), the current Return-on-Tangible-Equity is 18.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bangkok Dusit Medical Services PCL (BKK:BDMS) Overvalued in 2026?
Based on GuruFocus' analysis, Bangkok Dusit Medical Services PCL stock appears to be undervalued.
The current stock price of ฿19.40 is trading 30.9% below its estimated GF Value™ of ฿28.09.
GuruFocus considers Bangkok Dusit Medical Services PCL to be Significantly Undervalued.
Key valuation signals for BKK:BDMS:
Return-on-Tangible-Equity: 18.51% (near median its 10-year median of 19.52)
GF Value™: ฿28.09 vs. price of ฿19.40 (30.9% below fair value)
Industry Position: 81.3% above the Healthcare Providers & Services median (#198 of 579)
No single metric tells the full story. See the BKK:BDMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bangkok Dusit Medical Services PCL Business Description
Bangkok Dusit Medical Services PCL operates a network of private hospitals in Thailand and some overseas markets, under the Bangkok Hospital, Phyathai Hospital, Samitivej Hospital, Paolo Hospital, BNH Hospital, and Royal International Hospital brands. The company has two business segments, namely hospital operations and other businesses that support hospital business, such as medical laboratories, production and distribution of pharmaceutical products/medical equipment/saline, pharmacies, asset management for healthcare business, accounting services, technology and information services, training business, and insurance broker. The company's hospital operations generate the vast majority of its revenue.
90GF Score
Get the complete analysis for BKK:BDMS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BDMS has been successfully added to your 
